Wed, Aug 20, 2014, 7:09 AM EDT - U.S. Markets open in 2 hrs 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Elan Corporation, plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • acricketeer acricketeer Mar 1, 2005 6:32 PM Flag

    AGREE

    That's the issue here. Neurologists would be reluctant to use a drug that could further demyelinate their patients' sheaths. Enbrel is used for rheumatooid arthritis and some other off label uses, including psoriatic arthritis. Remicade is also used for Crohn's disease. Neither of these two drugs are used specifically for MS. Considering the latest finding with Tysabri, which is in a similar pharmacologic class, we might see a warning label with these two other drugs, not to use it with MS patients. Another possible outcome for Tysabri is that it may go back on the market within a year or so for Crohn's, but not for MS. The verdict is still out and we'll have to wait for data. I expect to see more data by the time of the April Neurology Meeting.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.